More therapies are coming on the market with price tags over CHF100,000 and limited clinical evidence, creating new challenges for health insurers.
Keystone-SDA
In a bid to lower healthcare costs, the Swiss parliament is considering measures on drug pricing that are drawing the ire of some health experts. What’s behind the measures and why are they stirring…
